Royalty Pharma Stock Forecast

Stock Price Forecast

The 6 analysts that cover Royalty Pharma stock have a consensus rating of "Strong Buy" and an average price target of $55.17, which forecasts a 3.61% increase in the stock price over the next year. The lowest target is $42 and the highest is $66.

Price Target: $55.17 (+3.61%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$42	$55.17	$58	$66
Change	-21.13%	+3.61%	+8.92%	+23.94%

Analyst Ratings

The average analyst rating for Royalty Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	3	4	4	4	4	4
Buy	1	1	1	1	1	2
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	4	5	5	5	5	6

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Geoff Meacham Citigroup	Citigroup	Strong Buy Maintains $50 → $66	Strong Buy	Maintains	$50 → $66	+23.94%	May 7, 2026
Chris Schott JP Morgan	JP Morgan	Buy Maintains $50 → $58	Buy	Maintains	$50 → $58	+8.92%	May 7, 2026
Ashwani Verma UBS	UBS	Strong Buy Maintains $51 → $57	Strong Buy	Maintains	$51 → $57	+7.04%	Apr 21, 2026
Terence Flynn Morgan Stanley	Morgan Stanley	Buy Maintains $61 → $63	Buy	Maintains	$61 → $63	+18.31%	Apr 10, 2026
Ashwani Verma UBS	UBS	Hold → Strong Buy Upgrades $38 → $49	Hold → Strong Buy	Upgrades	$38 → $49	-7.98%	Jan 30, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

3.31B

from 2.38B

38.97%

from 2.38B

Revenue Next Year

3.47B

from 3.31B

5.02%

from 3.31B

EPS This Year

5.29

from 1.78

197.02%

from 1.78

EPS Next Year

5.63

from 5.29

6.48%

from 5.29

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	2.29B	2.24B	2.35B	2.26B	2.38B	3.31B	3.47B
Revenue Growth	7.87%	-2.28%	5.24%	-3.86%	5.06%	38.97%	5.02%
EPS	1.49	0.10	2.53	1.91	1.78	5.29	5.63
EPS Growth	12.97%	-93.44%	2,490.74%	-24.54%	-6.83%	197.02%	6.48%
Forward PE	-	-	-	-	-	10.06	9.45
No. Analysts	-	-	-	-	-	12	12

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027
High	3.7B	4.0B
Avg	3.3B	3.5B
Low	2.6B	2.6B

Revenue Growth

Revenue Growth	2026	2027
High	53.9%	21.1%
Avg	39.0%	5.0%
Low	8.4%	-21.3%

EPS Forecast

EPS	2026	2027
High	5.55	6.17
Avg	5.29	5.63
Low	4.96	4.83

EPS Growth

EPS Growth	2026	2027
High	211.8%	16.7%
Avg	197.0%	6.5%
Low	178.2%	-8.7%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.